A detailed history of Lazard Asset Management LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 8,828 shares of CTMX stock, worth $8,828. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,828
Previous 18,481 52.23%
Holding current value
$8,828
Previous $22,000 54.55%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.12 - $1.51 $10,811 - $14,576
-9,653 Reduced 52.23%
8,828 $10,000
Q2 2024

Aug 14, 2024

BUY
$1.21 - $5.13 $20,888 - $88,559
17,263 Added 1417.32%
18,481 $22,000
Q1 2024

May 14, 2024

SELL
$1.41 - $2.74 $46 - $90
-33 Reduced 2.64%
1,218 $2,000
Q4 2023

Feb 14, 2024

BUY
$1.07 - $1.55 $1,338 - $1,939
1,251 New
1,251 $1,000
Q1 2022

May 13, 2022

BUY
$2.67 - $4.68 $40,546 - $71,070
15,186 New
15,186 $40,000
Q1 2021

May 14, 2021

SELL
$6.6 - $9.0 $54,727 - $74,628
-8,292 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$6.47 - $7.9 $53,649 - $65,506
8,292 New
8,292 $54,000
Q3 2020

Nov 13, 2020

SELL
$6.55 - $8.83 $6,307 - $8,503
-963 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$7.4 - $14.64 $359,913 - $712,045
-48,637 Reduced 98.06%
963 $8,000
Q4 2019

Feb 13, 2020

SELL
$5.17 - $8.91 $8,272 - $14,256
-1,600 Reduced 3.13%
49,600 $412,000
Q1 2019

May 13, 2019

BUY
$9.5 - $19.16 $114,000 - $229,920
12,000 Added 30.61%
51,200 $550,000
Q3 2018

Nov 13, 2018

BUY
$18.04 - $26.41 $707,168 - $1.04 Million
39,200 New
39,200 $725,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.